about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyNivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experiencePazopanib and pancreatic toxicity: a case report.Predicting Molecular Models: Where Are We Going?Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?What advances have been made in immune-therapy for renal cell carcinoma?Immunotherapy advances in uro-genital malignancies.Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors.Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.Multimodal treatment of advanced renal cancer in 2017.Combination therapies for patients with metastatic renal cell carcinoma.Castration-naive metastatic prostate cancer: reshaping old paradigms.Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis.Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeImproved quality of life is the way to longer lifeDoes F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
P50
Q26741450-EA3CBDAB-6771-43D5-90D6-4C8244B13CB1Q28068959-A2548ACC-1786-452A-87C5-00DDAC70A1B3Q35616735-248F3451-CD8E-44F6-91FF-E4D8BABC6F6CQ38255286-7B567F48-CA70-4213-A203-EA5D4B835BBFQ38628043-E10E47B6-79D5-43E8-9FBA-633E5D0EA66EQ38759282-45764A53-5515-4429-B2C4-CA81F2A1A366Q38884218-E4A194D7-5CA7-4B77-B21D-EBFC0640CB5EQ38956775-0555B0AA-294E-48EF-9620-7512F83F6AC9Q40527144-BF785B33-3154-45B4-ACA4-E975AA2D1B02Q42150505-59DECE89-A7BF-4110-B9CC-406706280DB8Q47136435-696283FC-A63D-468E-85E5-EE16BC1F0D47Q47550490-B2D61765-1EB6-46EE-89A8-FE4F54BD7BCCQ50030018-09DA5C97-B0C0-44A7-A418-F8292252D376Q50270201-2BC3C413-46BA-44AD-980B-46482AABCC19Q52686179-9FA71619-7E9A-4CBC-9FF3-847F9D5A5FD5Q53249055-5DA349E3-A53D-479B-8F0D-E5ECFBE70568Q61447523-D21712F9-EFAA-4EE9-9C9D-2436BE415B95Q87632418-885D753D-8B60-4015-B5B0-BBBE17FF1CE4Q89491898-59130B39-AAB1-41F7-BAF9-88F4E6DF7B32
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Raffaele Ratta
@ast
Raffaele Ratta
@en
Raffaele Ratta
@es
Raffaele Ratta
@nl
type
label
Raffaele Ratta
@ast
Raffaele Ratta
@en
Raffaele Ratta
@es
Raffaele Ratta
@nl
prefLabel
Raffaele Ratta
@ast
Raffaele Ratta
@en
Raffaele Ratta
@es
Raffaele Ratta
@nl
P106
P1153
6507654301
P21
P31
P496
0000-0002-4972-9666